DexCom, Inc. (DXCM) Down 5.1% — Is It Smart to Take Money Off the Table?
DexCom, Inc. (DXCM) is under heavy pressure this Friday, last changing hands at $80.17 on the NASDAQ — down $4.29 from the prior close of $84.46. The decline leaves the stock about 13.4% below its 52-week high of $92.59, reached on August 24, 2026. Most of the ground gained during the late-summer run has now been surrendered in a matter of sessions.
Volume stands at roughly 1.59 million shares with the session still open, about 35% of the 90-day average of approximately 4.57 million. The selling has been sharp in price terms but has not yet come with outsized turnover.
Why DexCom, Inc. Price is Moving Lower
The most plausible driver is a sector read-through from Insulet (PODD). On November 4, Insulet said its 2027 growth would come in modestly below its prior mid-teens outlook and cited new competition and slower international growth. That warning goes to the core question investors ask about diabetes-device makers, which is how long growth rates can hold up as the market matures and competition intensifies. Insulet shares were down about 8% intraday on November 6, and DexCom is moving in the same direction. This is not a broad-market selloff. At the morning snapshot, the S&P 500 was up 1.08% and the Nasdaq was up 1.83%, so the weakness is concentrated in medical technology rather than spread across equities.
Other medical-device names are also lower, which reinforces the sector framing. Intuitive Surgical, Inc. (ISRG) is down 3.19% and Abbott Laboratories (ABT) has slid 2.74%. Abbott's move matters here because it competes directly with DexCom in continuous glucose monitoring. Today's drop extends DexCom's 4.54% decline on November 5. Across the two sessions, the stock has more than erased the 6.64% gain it posted on November 4.
The selling does not trace back to DexCom's own results. On October 29, the company reported Q3 adjusted EPS of $0.73 against a $0.67 estimate, up from $0.61 a year earlier. Revenue of $1.344 billion topped the roughly $1.32 billion consensus and rose 11% year over year. Gross margin widened to 65.1% from 61.3%, and management lifted its 2026 revenue outlook to $5.20 billion–$5.25 billion from $5.18 billion–$5.25 billion. The higher outlook came entirely from raising the low end of the range, with the top unchanged. That cautious adjustment gives investors little defense against a competitor's warning about 2027 growth across the category.
What is the DexCom, Inc. Rating - Should I Sell?
Weiss Ratings assigns DXCM a C+ rating. Current recommendation is Hold. The C+ reflects a business that is operating well, held back by a stock that has been difficult to own. Today's sector-driven slide shows that tension clearly.
The fundamentals are strong. DexCom is rated Excellent on the Growth Index, a rating supported by 11.18% revenue growth and the 11% year-over-year increase in the latest quarter. That pace is solid for a company with more than $5 billion in annual sales. The Excellent rating on the Efficiency Index rests on a 37.67% return on equity and a 19.41% profit margin. The Q3 gross margin expansion to 65.1% suggests manufacturing scale on the G7 platform is starting to pay off. An Excellent Solvency Index rating rounds out the picture, indicating the balance sheet can handle competitive pressure without financial strain.
The picture becomes more nuanced in the market-based measures. The stock is rated Fair on the Total Return Index, which fits a share price sitting 13.4% below its August high despite a quarter of beats and a modestly raised outlook. The Weak Volatility Index reflects the kind of swings seen this week: a 6.64% gain followed by back-to-back declines of 4.54% and roughly 5%, driven largely by a competitor's guidance rather than DexCom's own numbers. A forward P/E of 34.68 adds to the sensitivity. At that valuation, any doubt about the category's 2027 growth is quickly reflected in the price.
Within the Health Care sector, DexCom is on par with CVS Health Corporation (CVS, C+) and sits a notch above Abbott Laboratories (ABT, C), Intuitive Surgical, Inc. (ISRG, C), and Stryker Corporation (SYK, C). That edge reflects DexCom's stronger fundamental ratings. It is not enough to lift the stock into Buy territory while the price remains this volatile.
About DexCom, Inc.
DexCom, Inc. (DXCM) is a Health Care company focused on continuous glucose monitoring for people with diabetes. Founded in 1999 and headquartered in San Diego, California, the company makes wearable sensor systems that measure glucose levels throughout the day and send readings to a smartphone app or receiver. This replaces much of the burden of fingerstick testing.
The flagship Dexcom G7 combines the sensor and transmitter into a single compact wearable. The Dexcom G6 remains in use across a large installed base. The company has also moved beyond its core insulin-using population with Stelo, an over-the-counter biosensor aimed at people with type 2 diabetes who do not use insulin. Internationally, offerings such as Dexcom ONE+ target more cost-sensitive markets. DexCom's systems integrate with automated insulin delivery systems from partners, which places its sensors at the center of closed-loop diabetes management.
DexCom's competitive position rests on clinical accuracy, a long record in intensive-insulin users, broad reimbursement coverage, and a large base of recurring sensor revenue, since patients replace sensors on a regular schedule. That recurring model gives the business durable revenue visibility. The CGM market is nonetheless contested, with Abbott's FreeStyle Libre franchise a formidable rival on scale and price. Pricing pressure and competitive share shifts remain the key variables in the category's long-term economics.
Investor Outlook
DexCom (DXCM) carries a Weiss Rating of C+ (Hold). The underlying business is performing well, but the stock is exposed to sector-wide doubts about how long diabetes-device growth can be sustained. Investors should watch whether the competitive and international pressures Insulet flagged appear in DexCom's own commentary, whether gross margin holds near 65%, and whether early 2027 guidance supports a forward P/E in the mid-30s. See full rankings of all C+ rated Health Care stocks inside the Weiss Stock Screener.
--